{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-008949","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.793835+00:00","generated_at":"2026-05-15T09:38:22.918671+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Moleculin reports FY2025 results; MIRACLE trial shows 40% blinded CRc rate in first 30 R/R AML patients","bullets":["FY2025 R&D expense $15.9M (down from $17.7M), G&A $9.2M; cash $8.9M at year-end; $8.3M raised in Q1 2026; cash runway into Q3 2026.","MIRACLE trial (Phase 2B/3) Annamycin + cytarabine in R/R AML: blinded CRc 40% in first 30 subjects; interim unblinding for 45 patients expected mid-2026.","Pipeline progress: WP1066 Phase 1 pediatric brain tumor trial shows safety and immune response; Annamycin GBM collaboration and pancreatic cancer study initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-008949","json":"https://secwatch.observer/filing/0001437749-26-008949.json","markdown":"https://secwatch.observer/filing/0001437749-26-008949.md","text":"https://secwatch.observer/filing/0001437749-26-008949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/0001437749-26-008949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/mbrx20260317_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:38:22.918671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86f5792c035a1b26321e6096cc8bf6686592e2f1","claim":"Moleculin Biotech, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/0001437749-26-008949-index.htm","confidence":0.68,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}